Loading…
SPRY
ARS Pharmaceuticals, Inc.
NASDAQ· Healthcare· Biotechnology
$5.89-2.32%
Key metrics
- Market cap
- $585.74M
- P/E
- —
- Forward P/E
- —
- P/B
- 46.7x
- Dividend yield
- —
- EPS
- -$2.18
- ROE
- -210.35%
- Profit margin
- -184.25%
- Revenue growth
- +114.20%
- Beta
- 0.97
- 52-week high
- $13.15
- 52-week low
- $4.91
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
- 195
- San Diego, United States
Company description provided by Yahoo Finance.